Cyclo (-RGDfC): Benchmark αvβ3 Integrin Binding Cyclic Peptide for Tumor Targeting and Angiogenesis Research

Executive Summary: Cyclo (-RGDfC) is a synthetic cyclic RGD peptide designed for high-affinity, selective binding to the αvβ3 integrin receptor, a key mediator of cell adhesion, migration, and angiogenesis in cancer models (APExBIO). The c(RGDfC) structure provides enhanced receptor specificity and stability over linear RGD peptides (FexinidazoleChem). It is insoluble in ethanol or water but dissolves efficiently in DMSO at ≥49 mg/mL, facilitating integration into biochemical and cellular assays. Purity is typically ≥98%, supported by HPLC, MS, and NMR validation. APExBIO’s A8790 kit is widely used in integrin signaling, tumor targeting, and angiogenesis research, with applications in targeted delivery, high-throughput biomaterials, and mechanistic studies (ISCVFA).

Biological Rationale

Integrins are heterodimeric transmembrane receptors mediating cell-extracellular matrix (ECM) interactions. The αvβ3 integrin is highly expressed in tumor endothelium and certain cancer cells, where it regulates adhesion, migration, and neovascularization (FexinidazoleChem). RGD peptides, especially their cyclic variants like Cyclo (-RGDfC), exploit the Arg-Gly-Asp motif to achieve high-affinity αvβ3 binding, blocking native ligand engagement. This targeting impairs angiogenic signaling and tumor cell migration—processes central to malignancy progression. High αvβ3 expression is a negative prognostic marker in cancers such as osteosarcoma, melanoma, and glioblastoma (AmericaPeptides).

Mechanism of Action of Cyclo (-RGDfC)

Cyclo (-RGDfC) presents the RGD motif in a conformationally constrained loop, enhancing affinity for the αvβ3 integrin over linear peptides. Upon binding, it competitively inhibits endogenous ECM ligands (e.g., vitronectin, fibronectin) at the integrin’s ligand-binding pocket. This blockade disrupts integrin clustering and downstream signaling cascades, including focal adhesion kinase (FAK), PI3K/AKT, and MAPK pathways. The result is impaired cell adhesion, migration, and survival signaling in affected cell types (SolifenacinCompound). Cyclo (-RGDfC) can be conjugated to drugs, dyes, or nanocarriers, enabling targeted delivery to αvβ3-expressing cells.

Evidence & Benchmarks

• Cyclo (-RGDfC) binds αvβ3 integrin with nanomolar affinity, outperforming linear RGD peptides in competitive binding assays (see APExBIO technical data).
• c(RGDfC) inhibits integrin-mediated adhesion and migration in tumor cell lines under serum-free conditions (FexinidazoleChem).
• Conjugation of Cyclo (-RGDfC) to delivery vehicles (e.g., nanoparticles, proteins) increases cellular uptake in αvβ3-positive cells by >3-fold compared to unconjugated controls (AmericaPeptides).
• In high-throughput hydrogel platforms, c(RGDfC) maintains spatial pattern fidelity and supports reproducible cell adhesion at concentrations as low as 1 μM per well (ISCVFA).
• In canine osteosarcoma models, high αvβ3 expression correlates with poor prognosis and metastatic potential (Royals et al., AJVR 2005).

This article extends prior coverage (FexinidazoleChem) by providing detailed, actionable parameters and highlighting APExBIO’s rigorous QC standards for Cyclo (-RGDfC).

Applications, Limits & Misconceptions

Cyclo (-RGDfC) is used extensively in cancer research, angiogenesis assays, biomaterials engineering, and targeted drug delivery. Its high specificity for αvβ3 supports selective targeting in both in vitro and in vivo models. Common formats include surface immobilization, solution-phase ligand, and conjugate for drug/protein delivery. For advanced biomaterials and programmable cell systems, Cyclo (-RGDfC) enables spatial patterning and controlled cell-matrix interactions (Peptide-YY).

Common Pitfalls or Misconceptions

• Not a universal integrin inhibitor: Cyclo (-RGDfC) is selective for αvβ3 and has significantly reduced affinity for other integrins (e.g., α5β1, αvβ5).
• Solubility limitations: The peptide is insoluble in water and ethanol; DMSO is required at ≥49 mg/mL for effective dissolution (APExBIO).
• Not for diagnostic/therapeutic use: APExBIO’s A8790 is for research purposes only and not approved for clinical diagnostics or therapy.
• Short-term solution stability: Peptide solutions should be prepared fresh and used promptly to avoid loss of activity.
• Not a stand-alone anti-tumor agent: While it blocks integrin function, Cyclo (-RGDfC) does not induce cytotoxicity or apoptosis by itself in most cell lines.

Workflow Integration & Parameters

For optimal results, Cyclo (-RGDfC) (A8790) should be stored at -20°C in lyophilized form and protected from light. For use, dissolve in DMSO at ≥49 mg/mL; further dilute in assay buffer as required. Typical working concentrations range from 0.1 μM to 10 μM, depending on assay format and cell type. Surface coating protocols require uniform peptide distribution and thorough washing to remove unbound material. For conjugation, standard NHS-ester or maleimide chemistries can be used to attach Cyclo (-RGDfC) to proteins or nanoparticles. Purity is confirmed by HPLC, mass spectrometry, and NMR, with batch certificates available from APExBIO. Routine applications include cell adhesion, migration, signal transduction, and high-content screening assays.

This article clarifies and updates SolifenacinCompound, emphasizing the solubility and storage parameters critical for reproducibility in advanced workflows.

Conclusion & Outlook

Cyclo (-RGDfC) is a validated, high-specificity αvβ3 integrin binding cyclic peptide supporting advanced tumor targeting and angiogenesis research. Its robust performance in cell adhesion, migration, and biomaterials assays makes it a cornerstone reagent for mechanistic and translational research. As integrin-targeted strategies expand in cancer and regenerative medicine, standardized, high-QC reagents like APExBIO’s Cyclo (-RGDfC) will remain essential for reproducibility and innovation. Future advances may include engineered variants with expanded integrin selectivity or enhanced in vivo stability.

For further mechanistic insights and translational strategies, see AmericaPeptides, which contrasts current best practices in hydrogel-based and device-enabled applications.

Product details, batch certificates, and ordering information are available at APExBIO Cyclo (-RGDfC).